{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T10:49:38Z","timestamp":1775818178627,"version":"3.50.1"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"36","license":[{"start":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T00:00:00Z","timestamp":1662681600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9,9]]},"abstract":"<jats:sec>\n            <jats:title>Introduction:<\/jats:title>\n            <jats:p>The indications for immune checkpoint inhibitors (ICIs) are expanding for various cancers because of their durable responses and tolerable safety profiles. Immune-related adverse events (irAEs), including neurological adverse events (nAEs), are associated with ICIs therapy. However, there have been few studies on whether re-challenge with ICIs can be clinically acceptable after neurological AE has improved.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 69-year-old woman with recurrent ovarian cancer undergoing palliative chemotherapy was admitted to our hospital with sudden development of diplopia, dizziness, and gait instability. The patient was administered ICI therapy with anti-angiogenic agents for 9 weeks for 3 cycles.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>We performed neurological examination, brain imaging, nerve conduction studies, and serology tests. The patient was diagnosed with Guillain\u2013Barr\u00e9 syndrome variant, an immune-mediated polyneuropathy characterized by a triad of ataxia, areflexia, and ophthalmoplegia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Intervention:<\/jats:title>\n            <jats:p>After prompt discontinuation of pembrolizumab, the patient was taken intravenous methylprednisolone (2\u2009mg\/kg) was administered for 5 days, and her symptoms were partially resolved. With the addition of immunoglobulin 0.4\u2009g\/kg for 5 days, her symptoms gradually improved.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>The patient\u2019s neurological symptoms improved after immunosuppressive therapy, without sequelae. The NCV showed normal nerve conduction. Unfortunately, because there was little evidence for pembrolizumab rechallenge, pembrolizumab therapy was permanently discontinued, and the tumors eventually progressed.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000030236","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T20:05:12Z","timestamp":1662753912000},"page":"e30236","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":[": A case report of re-challenge of immune checkpoint inhibitors after immune-related neurological adverse events: Review of literature"],"prefix":"10.1097","volume":"101","author":[{"given":"Heesung","family":"Moon","sequence":"first","affiliation":[{"name":"CHA University, School of Medicine, Seongnam, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1641-4059","authenticated-orcid":false,"given":"Seul-Gi","family":"Kim","sequence":"additional","affiliation":[{"name":"Hematology and Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Ki","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Surgery, CHA Bundang Medical Center, CHA University, Seongnam, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinkwon","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Neurology, Yongin Severance Hospital, Yonsei University College of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Ryeol","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Urology, CHA Bundang Medical Center, CHA University, Seongnam, Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong Wha","family":"Moon","sequence":"additional","affiliation":[{"name":"Hematology and Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.3390\/molecules24061190","article-title":"Molecular interactions of antibody drugs targeting PD-1, PD-L1, and CTLA-4 in immuno-oncology.","volume":"24","author":"Lee","year":"2019","journal-title":"Molecules"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy.","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1200\/JCO.19.00934","article-title":"Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study.","volume":"37","author":"Garon","year":"2019","journal-title":"J Clin Oncol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (SITC) toxicity management working group.","volume":"5","author":"Puzanov","year":"2017","journal-title":"J ImmunoTher Cancer"},{"key":"R5-20250504","first-page":"311","article-title":"Corrigendum: current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy.","volume":"8","author":"Kumar","year":"2017","journal-title":"Front Pharmacol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.3390\/ijms18112291","article-title":"Synergies of targeting tumor angiogenesis and immune checkpoints in non-small cell lung cancer and renal cell cancer: from basic concepts to clinical reality.","volume":"18","author":"Pircher","year":"2017","journal-title":"Int J Mol Sci"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1159\/000477162","article-title":"PD-1 Checkpoint inhibitor associated autoimmune encephalitis.","volume":"10","author":"Schneider","year":"2017","journal-title":"Case Rep Oncol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1001\/jamaneurol.2016.1399","article-title":"Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer.","volume":"73","author":"Williams","year":"2016","journal-title":"JAMA Neurol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","article-title":"Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy.","volume":"60","author":"Zimmer","year":"2016","journal-title":"Eur J Cancer"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"880","DOI":"10.12659\/AJCR.900941","article-title":"Nivolumab-induced severe akathisia in an advanced lung cancer patient.","volume":"17","author":"Abe","year":"2016","journal-title":"Am J Case Rep"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/annonc\/mdw558","article-title":"Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature.","volume":"28","author":"Spain","year":"2017","journal-title":"Ann Oncol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/practneurol-2012-000447","article-title":"Neurological immune-related adverse events of ipilimumab.","volume":"13","author":"Bot","year":"2013","journal-title":"Pract Neurol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1093\/annonc\/mdr028","article-title":"Anti-CTLA-4 antibody-induced guillain-barre syndrome in a melanoma patient.","volume":"22","author":"Wilgenhof","year":"2011","journal-title":"Ann Oncol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1200\/JCO.2013.51.1683","article-title":"Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma.","volume":"33","author":"Johnson","year":"2015","journal-title":"J Clin Oncol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/CMR.0000000000000310","article-title":"Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients.","volume":"27","author":"Nguyen","year":"2017","journal-title":"Melanoma Res"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jamaoncol.2019.1022","article-title":"Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer.","volume":"5","author":"Simonaggio","year":"2019","journal-title":"JAMA Oncol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/annonc\/mdx642","article-title":"Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma.","volume":"29","author":"Pollack","year":"2018","journal-title":"Ann Oncol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/ana.25708","article-title":"Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum.","volume":"87","author":"Dubey","year":"2020","journal-title":"Ann Neurol"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab.","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1136\/annrheumdis-2018-214336","article-title":"Immune checkpoint inhibitor rechallenge in patients with immune-related myositis.","volume":"78","author":"Delyon","year":"2019","journal-title":"Ann Rheum Dis"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000030236","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T05:31:35Z","timestamp":1746336695000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000030236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,9]]},"references-count":20,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000030236","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,9]]}}}